Adapt Faces Tough Questions in Bid to Revive Narcan Patents

Director John Christopher “J.C.” Rozendaal was mentioned as representing Teva Pharmaceuticals in the article “Adapt Faces Tough Questions in Bid to Revive Narcan Patents,” published by Bloomberg Law. From the article:

“Adapt Pharma Inc.’s arguments were met with skepticism from two judges as it tried to convince the Federal Circuit to revive its four patents on Narcan opioid overdose treatment felled by Teva Pharmaceuticals USA Inc.

A ruling from the U.S. District Court for the District of New Jersey invalidated the patents as obvious, paving the way for drug companies like Teva to make generic versions of the nasal spray 15 years earlier than if the patents were allowed to expire.”